|Mr. Gareth Sheridan||CEO & Director||57k||N/A||1990|
|Mr. Sean Gallagher||Pres & Director||N/A||N/A||1963|
|Dr. Jeffrey Patrick||Chief Scientific Officer & Head of Scientific Advisory Board||N/A||N/A||1970|
|Mr. Gerald Goodman||CFO & Chief Accounting Officer||N/A||N/A||1948|
|Dr. Alan Smith||COO & Pres of 4P Therapeutics||N/A||N/A||1966|
|Mr. Patrick Ryan||Chief Technical Officer||N/A||N/A||1987|
|Dr. Larry M. Dillaha||Chief Medical Officer & Member of Scientific Advisory Board||N/A||N/A||1964|
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. Its product line consists of an energy patch line; a weight management patch line; a multivitamin patch line; a children's multivitamin patch line; an amino acid patch line; an anti-wrinkle patch line; an insect repellant patch line; a detox patch line; a PMS patch line; a sleep patch line; and a nausea and motion sickness patch line. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Nutriband Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.